Logo image of TLSA

TIZIANA LIFE SCIENCES LTD (TLSA) Stock Fundamental Analysis

USA - NASDAQ:TLSA - BMG889121031 - Common Stock

1.95 USD
-0.07 (-3.47%)
Last: 10/17/2025, 8:00:01 PM
1.8906 USD
-0.06 (-3.05%)
After Hours: 10/17/2025, 8:00:01 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to TLSA. TLSA was compared to 536 industry peers in the Biotechnology industry. The financial health of TLSA is average, but there are quite some concerns on its profitability. TLSA is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year TLSA has reported negative net income.
In the past year TLSA has reported a negative cash flow from operations.
TLSA had negative earnings in each of the past 5 years.
In the past 5 years TLSA always reported negative operating cash flow.
TLSA Yearly Net Income VS EBIT VS OCF VS FCFTLSA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

With a Return On Assets value of -77.37%, TLSA is not doing good in the industry: 66.36% of the companies in the same industry are doing better.
The Return On Equity of TLSA (-139.58%) is worse than 61.87% of its industry peers.
Industry RankSector Rank
ROA -77.37%
ROE -139.58%
ROIC N/A
ROA(3y)-83.77%
ROA(5y)-135.3%
ROE(3y)-151.66%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TLSA Yearly ROA, ROE, ROICTLSA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 -1K -1.5K

1.3 Margins

TLSA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TLSA Yearly Profit, Operating, Gross MarginsTLSA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023

More info and screens

6

2. Health

2.1 Basic Checks

The number of shares outstanding for TLSA has been increased compared to 1 year ago.
The number of shares outstanding for TLSA has been increased compared to 5 years ago.
The debt/assets ratio for TLSA has been reduced compared to a year ago.
TLSA Yearly Shares OutstandingTLSA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
TLSA Yearly Total Debt VS Total AssetsTLSA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

An Altman-Z score of 13.70 indicates that TLSA is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 13.70, TLSA belongs to the top of the industry, outperforming 86.17% of the companies in the same industry.
TLSA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 13.7
ROIC/WACCN/A
WACCN/A
TLSA Yearly LT Debt VS Equity VS FCFTLSA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

2.3 Liquidity

TLSA has a Current Ratio of 1.72. This is a normal value and indicates that TLSA is financially healthy and should not expect problems in meeting its short term obligations.
TLSA's Current ratio of 1.72 is on the low side compared to the rest of the industry. TLSA is outperformed by 79.25% of its industry peers.
A Quick Ratio of 1.72 indicates that TLSA should not have too much problems paying its short term obligations.
With a Quick ratio value of 1.72, TLSA is not doing good in the industry: 78.13% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.72
Quick Ratio 1.72
TLSA Yearly Current Assets VS Current LiabilitesTLSA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

0

3. Growth

3.1 Past

TLSA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 14.91%, which is quite good.
EPS 1Y (TTM)14.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-6.87%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to decrease by -10.06% on average over the next years. This is quite bad
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y13.33%
EPS Next 2Y-9.54%
EPS Next 3Y-10.06%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
TLSA Yearly Revenue VS EstimatesTLSA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 100M 200M 300M 400M 500M
TLSA Yearly EPS VS EstimatesTLSA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 -0.1 -0.2 -0.3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

TLSA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TLSA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TLSA Price Earnings VS Forward Price EarningsTLSA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TLSA Per share dataTLSA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.05 -0.05 -0.1 -0.15

4.3 Compensation for Growth

A cheap valuation may be justified as TLSA's earnings are expected to decrease with -10.06% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-9.54%
EPS Next 3Y-10.06%

More info and screens

0

5. Dividend

5.1 Amount

TLSA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TIZIANA LIFE SCIENCES LTD

NASDAQ:TLSA (10/17/2025, 8:00:01 PM)

After market: 1.8906 -0.06 (-3.05%)

1.95

-0.07 (-3.47%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-13 2025-10-13
Earnings (Next)N/A N/A
Inst Owners4.15%
Inst Owner Change0.67%
Ins Owners43.06%
Ins Owner ChangeN/A
Market Cap231.70M
Analysts82.86
Price Target8.16 (318.46%)
Short Float %1.75%
Short Ratio2.42
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)166.67%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 25.18
P/tB 25.18
EV/EBITDA N/A
EPS(TTM)-0.11
EYN/A
EPS(NY)-0.18
Fwd EYN/A
FCF(TTM)-0.07
FCFYN/A
OCF(TTM)-0.07
OCFYN/A
SpS0
BVpS0.08
TBVpS0.08
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -77.37%
ROE -139.58%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-83.77%
ROA(5y)-135.3%
ROE(3y)-151.66%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 7.33%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.72
Quick Ratio 1.72
Altman-Z 13.7
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)14.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-6.87%
EPS Next Y13.33%
EPS Next 2Y-9.54%
EPS Next 3Y-10.06%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-16.93%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y57.54%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y57.59%
OCF growth 3YN/A
OCF growth 5YN/A